Digging Deeper Into the TP53 Mutation in AML with Rory Shallis, MD, Yale

The TP53 mutation in AML is considered to be a high risk mutation and occurs in approximately 5-10% of patients. This genetic mutation has been difficult to treat, often being chemoresistant with a poor prognosis, however, the research indicates progress is being made in this area. Join us live on Thursday, July 14th at 11 am EST to hear from Dr. Rory Shallis with Yale New Haven Hospital who will be discussing the TP53 mutation in AML, current treatment options available, and clinical trials using novel investigational agents. In this podcast, Dr. Shallis will tell us all about the TP53 mutation and the latest research and clinical trials involving investigational agents being used to target this mutation. There will be time at the end of the show to ask Dr. Shallis your questions directly! Thank you to our episode sponsor, Bristol Myers Squibb.